Current Report Articles
AHA and NRHA Comment on DEA Telehealth Rules
AHA Logo (March 31, 2023) – This week, the American Hospital Association and the National Rural Health Association announced the submission of comments in response to the Drug Enforcement Administration's proposed rules for the prescribing of controlled medications via telemedicine, including buprenorphine for opioid use disorder. The DEA is proposing to no longer allow DEA-registered practitioners to prescribe buprenorphine via telehealth without an in-person exam, with limited exceptions. AHA urged the DEA to establish a special registration process to waive the in-person evaluations for practitioners who register with the DEA. Until then, AHA strongly urged the agency to continue to waive the requirement as it has during the COVID-19 public health emergency. You can find AHA’s comments here. NRHA highlighted the restrictive and potentially dangerous disruption of care triggered by the proposed rule. You can find NRHA’s full summary here.
--Karen Braman